Related Experiment Videos

Rosiglitazone plus metformin: combination therapy for Type 2 diabetes

Stefano Del Prato1, Laura Volpe

  • 1Section of Diabetes, Department of Endocrinology and Metabolism, Ospedale Cisanello, Via Paradisa, 2, 56124 Pisa, Italy. delprato@immr.med.unipi.it

Expert Opinion on Pharmacotherapy
|May 28, 2004
PubMed

Insights

Combining metformin and thiazolidinediones effectively improves glycemic control in type 2 diabetes patients. This combination therapy addresses insulin resistance, a key factor in diabetes complications, offering a promising approach to managing the disease.

Area of Science:

  • Endocrinology and Metabolism
  • Cardiovascular Disease Research
  • Pharmacology

Background:

  • Type 2 diabetes is a prevalent condition linked to severe long-term complications, particularly cardiovascular disease.
  • Strict metabolic control is crucial for reducing disease burden, necessitating targeted therapies for pathogenetic defects like insulin resistance.
  • Obesity exacerbates insulin resistance, contributing to impaired glucose homeostasis, dyslipidemia, hypertension, inflammation, and endothelial dysfunction, all increasing cardiovascular risk.

Purpose of the Study:

  • To evaluate the efficacy and safety of combining metformin and thiazolidinediones for managing type 2 diabetes.
  • To assess the impact of this combination therapy on insulin sensitivity and cardiovascular risk factors.
  • To explore the benefits of a fixed-dose combination tablet for improved patient compliance and treatment outcomes.

Main Methods:

  • Review of clinical trials investigating the combined use of metformin and thiazolidinediones.
  • Analysis of drug mechanisms: metformin primarily affects hepatic glucose production, while thiazolidinediones enhance peripheral insulin sensitivity.
  • Comparison of combination therapy versus monotherapy regarding glycemic control (plasma glucose, HbA1c) and side effect profiles.

Main Results:

  • Combination therapy with metformin and thiazolidinediones demonstrates superior improvement in plasma glucose and HbA1c levels compared to monotherapy.
  • The combination therapy does not lead to an increased incidence of specific adverse side effects.
  • Development of a fixed-dose combination tablet offers enhanced convenience and may improve patient adherence.

Conclusions:

  • Combining metformin and thiazolidinediones provides an additive therapeutic effect in managing type 2 diabetes by targeting insulin resistance.
  • This combination represents a safe and effective strategy for achieving better glycemic control.
  • Further research is warranted to confirm the long-term cardiovascular benefits of aggressive insulin resistance intervention using this combined approach.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...